

Vijoice (alpelisib)
Effective 11/01/2022

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Vijoice is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Coverage Guidelines

Authorization may be reviewed for members new to the plan who are currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Member has a diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS)
2. Member is at least 2 years of age
3. The member has severe manifestations of disease and requires systemic therapy
4. Documented test confirming presence of PIK3CA mutation

Continuation of Therapy

Reauthorization will be granted for a covered indication and physician attestation that there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Limitations

1. Initial approvals will be granted for 6 months
2. Reauthorizations will be granted for 12 months.

Review History

09/21/2022 – Reviewed and created for July P&T. Effective 11/01/2022

References

Vioice [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2022.

